Is sino-nasal outcome test-22 reliable for guiding chronic rhinosinusitis patients for endoscopic sinus surgery?

Singla, Gifty; Singh, Mukhtiar; Singh, Ajmer; Kaur, Imrinder; Harsh, Kamlesh Kumar; Jasmeen, K

doi:10.4103/njcp.njcp_429_17

Cited by 9 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At present, the literature still lacks normative values of SNOT-22 in a European general population with an adequate sample size. Previous major fields of studies using SNOT-22 was rather on comparing pre- and postoperative HRQoL outcome of patients undergoing FESS 4 , 5 . Hopkins et al, who were the first to validate the SNOT-22 in the United Kingdom, employed the questionnaire in 2,077 surgical patients and obtained a preoperative score of 41.7 4 and an overall SNOT-22 score of 9.3 in 116 healthy participants.…”

Section: Discussionmentioning

confidence: 99%

“…The European position paper on rhinosinusitis and nasal polyps (EPOS) 2020 recommends subjective assessment of chronic rhinosinusitis symptoms in research and in clinical practice using validated questionnaires 3 . The Sino-Nasal Outcome Test 22 (SNOT-22) is a well-validated 4 , disease-specific instrument that combines rhinologic issues (physical problems and functional limitations) with general health issues (e.g., emotional domains) 5 . Because of its reliability, validity, responsiveness and easy application 6 , the SNOT-22 is considered to be the most suitable patient-reported outcome measure (PROM) for evaluating patients with CRS.…”

Section: Introductionmentioning

confidence: 99%

“…The Sino-Nasal Outcome Test 22 (SNOT-22) is a well-validated 4 , disease-specific instrument that combines rhinologic issues (physical problems and functional limitations) with general health issues (e.g., emotional domains) 5 . Because of its reliability, validity, responsiveness and easy application 6 , the SNOT-22 is considered to be the most suitable patient-reported outcome measure (PROM) for evaluating patients with CRS.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Normative data for interpreting the SNOT-22

Plath,

Sand,

Cavaliere

et al. 2023

Acta Otorhinolaryngol Ital

View full text Add to dashboard Cite

Objectives. The Sino-Nasal Outcome Test 22 (SNOT-22) is a validated patient-reported outcome instrument to evaluate the health-related quality of life (HRQoL) in patients with chronic rhinosinusitis (CRS). There are no published normative SNOT-22 scores, limiting its interpretation. Methods. Symptom scores from 1,000 SNOT-22 questionnaires were analysed by principal component analysis (PCA) and exploratory factor analyses. Data were derived from a survey with 1,000 healthy Europeans (reference cohort) who were recruited using the Respondi panel for market and social science research. This subsample was quoted to the population distribution of the German Microcensus and selected from a non-probability panel. Results. The overall normative SNOT-22 score can be detected to be 20.2 ± 19.44. Male (18.49 ± 19.15) and older (> 50 years old; 18.3 ± 17.49) participants had overall lower SNOT-22 mean results than females (21.8 ± 19.6) and younger (21.4 ± 20.55) participants, indicating higher levels of satisfaction. PCA proposed two SNOT-22 domains ("physiological well-being" and "psychological well-being"), which explained 65% of the variance. Conclusions. These are the first published (German) normative scores for the SNOT-22 and provide a clinical reference point for the interpretation of data.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Normative data for interpreting the SNOT-22

Plath,

Sand,

Cavaliere

et al. 2023

Acta Otorhinolaryngol Ital

View full text Add to dashboard Cite

show abstract

International consensus statement on allergy and rhinology: rhinosinusitis 2021

Orlandi

Kingdom

Smith

et al. 2021

Int Forum Allergy Rhinol

458

479

View full text Add to dashboard Cite

I. Executive Summary Background The 5 years since the publication of the first International Consensus Statement on Allergy and Rhinology: Rhinosinusitis (ICAR‐RS) has witnessed foundational progress in our understanding and treatment of rhinologic disease. These advances are reflected within the more than 40 new topics covered within the ICAR‐RS‐2021 as well as updates to the original 140 topics. This executive summary consolidates the evidence‐based findings of the document. Methods ICAR‐RS presents over 180 topics in the forms of evidence‐based reviews with recommendations (EBRRs), evidence‐based reviews, and literature reviews. The highest grade structured recommendations of the EBRR sections are summarized in this executive summary. Results ICAR‐RS‐2021 covers 22 topics regarding the medical management of RS, which are grade A/B and are presented in the executive summary. Additionally, 4 topics regarding the surgical management of RS are grade A/B and are presented in the executive summary. Finally, a comprehensive evidence‐based management algorithm is provided. Conclusion This ICAR‐RS‐2021 executive summary provides a compilation of the evidence‐based recommendations for medical and surgical treatment of the most common forms of RS.

show abstract

The predictive utility of the 22‐item sino‐nasal outcome test (SNOT‐22): A scoping review

Liu

Weitzel³

et al. 2021

Int Forum Allergy Rhinol

View full text Add to dashboard Cite

Background The 22‐item sino‐nasal outcome test (SNOT‐22) is a widely used and powerful patient‐reported outcomes measure for chronic rhinosinusitis (CRS). More recently; however, the SNOT‐22 has been evaluated as a predictive tool for multiple conditions. The objective of this scoping review is to investigate the extent to which SNOT‐22 is used in this manner and present this information in a way useful for clinicians. Methods A systematic search of PubMed, Scopus, Cochrane Library, and Web of Science was performed. Studies that evaluated SNOT‐22s predictive utility were considered for eligibility in this scoping review. Results A total of 39 studies met eligibility. The SNOT‐22 was found to be used as a predictive tool in three broad categories: (1) to predict a diagnosis, (2) to predict an outcome of an intervention, and (3) to predict a patient treatment preference. Thirteen studies were included in the diagnosis category, which made up ten different individual predictions. Twenty‐four studies were included in the outcomes category and investigated 17 different individual predictions. Finally, two studies were included in the patient preferences category, which together made one prediction. Conclusions The SNOT‐22 is a versatile tool that has the potential to be used in predicting various diagnoses, outcomes, and patient preferences. However, care must be taken in applying these predictions to clinical practice, as further research must be done in validating these predictions based on SNOT‐22 responses.

show abstract

Is sino-nasal outcome test-22 reliable for guiding chronic rhinosinusitis patients for endoscopic sinus surgery?

Cited by 9 publications

References 0 publications

Normative data for interpreting the SNOT-22

Normative data for interpreting the SNOT-22

International consensus statement on allergy and rhinology: rhinosinusitis 2021

The predictive utility of the 22‐item sino‐nasal outcome test (SNOT‐22): A scoping review

Contact Info

Product

Resources

About